TimothyJPluardMD

Breast Cancer

Koontz Endowed Chair in Breast Disease, University of Missouri, Kansas City School of Medicine. Director Saint Luke's Cancer Institute

Join to view full profile

Dr. Pluard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Pluard's full profile

Already have an account?

Office
4401 Wornall Rd
Kansas City, MO 64111
Phone+1 816-932-3800

Fax+1 816-932-3888
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1991 - 1993
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1987 - 1991
Washington University in St. Louis School of MedicineClass of 1987

Certifications & Licensure

MO State Medical License 1993 - 2025
KS State Medical License 2014 - 2024
FL State Medical License 2020 - 2022
TX State Medical License 1988 - 1992
American Board of Internal Medicine Medical Oncology

Clinical Trials

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer Start of enrollment: 2011 Sep 01
Terminated
Phase 2
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
Completed
Phase 2
Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer Start of enrollment: 2013 Jan 10
Terminated
Phase 3
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer Start of enrollment: 2013 Apr 01
Completed
Phase 2
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors Start of enrollment: 2013 May 03
Terminated
Phase 1, Phase 2
Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy Start of enrollment: 2013 Apr 04
Terminated
Not Applicable
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer Start of enrollment: 2018 Jul 06
Completed
Phase 2
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
Recruiting
Phase 3
Roles: Contact, Principal Investigator
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Start of enrollment: 2023 Oct 31
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique.
Emily J Gallagher, Heather Moore, Mario E Lacouture, Susan F Dent, Azeez Farooki, Marcus D Goncalves, Claudine Isaacs, Abigail Johnston, Dejan Juric, Zoe Quandt, Laura...> ;NPJ Breast Cancer. 2024 Jan 31
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
Cescon, D., Hilton, J., Morales Murilo, S., Layman, R., Pluard, T., Yeo, B., Park, I., Provencher, L., Kim, S., Im, Y., Wyce, A., Krishnatry, A., Hicks, K., Zhang, Q.,...> ;Clinical Cancer Research. 2024 Jan 17
1 citations
Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer: Overcoming Challenges in Genetic Testing and Clinical Considerations When Using Talazoparib.
Emily Brugioni, Elizabeth Cathcart-Rake, Janie Metsker, Elizabeth Gustafson, Lindsey Douglass, Timothy J Pluard> ;Clinical Breast Cancer. 2023 Jul 1
Bridging the Gap: Innovative 'Center for Precision Oncology' in Missouri.
Beth Gustafson, Lindsey Douglass, Timothy Pluard, Janakiraman Subramanian> ;Missouri Medicine. 2023 Mar 2
116 citations
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A P...
Linda M Liau, Keyoumars Ashkan, Steven Brem, Jian L Campian, John E Trusheim, Fabio M Iwamoto, David D Tran, George Ansstas, Charles S Cobbs, Jason A Heth, Michael E S...> ;JAMA Oncology. 2023 Jan 1
20 citations
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Pha...
Hope S Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D Pegram, Thomas Bachelot, Gail S Wright, Cristina Saura, Santiag...> ;Journal of Clinical Oncology. 2023 Jan 10
Hereditary Thrombophilia Testing Among Hospitalized Patients: Is It Warranted?
Omar K Abughanimeh, Rosalyn I Marar, Mohammad Tahboub, Anahat Kaur, Ayman Qasrawi, Mouhanna Abu Ghanimeh, Timothy Pluard> ;Cureus. 2022 May 1
13 citations
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer.
Cynthia X Ma, Jingqin Luo, Rachel A Freedman, Timothy J Pluard, Julie R Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason M Jones, Nancy U Lin, Eric P W...> ;Clinical Cancer Research. 2022 Apr 1
13 citations
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study.
Antoinette R Tan, Gail S Wright, Anu R Thummala, Michael A Danso, Lazar Popovic, Timothy J Pluard, Hyo S Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald A Richards...> ;Clinical Cancer Research. 2022 Feb 15
62 citations
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
Antoinette R. Tan, Gail S. Wright, Anu Thummala, Michael A. Danso, Lazar Popovic, Timothy J. Pluard, Hyo S Han, Željko Vojnović, Nikola Vasev, Ling Ma, Donald A. Richa...> ;The Lancet. Oncology. 2019 Nov 1
26 citations
Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinica...
Robin Imperial, Marjan Nazer, Zaheer Ahmed, Audrey E. Kam, Timothy J. Pluard, Waled Bahaj, Mia Levy, Timothy M. Kuzel, Dana M. Hayden, Sam G. Pappas, Janakiraman Subra...> ;Cancers. 2019 Sep 19
10 citations
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.
Denise A. Yardley, Lowell L. Hart, Anne Favret, Sibel Blau, Sami Diab, Donald A. Richards, Joseph A. Sparano, J. Thad Beck, Paul Richards, Patrick J. Ward, Bhuvaneswar...> ;Clinical Breast Cancer. 2019 Feb 28
2 citations
Diffuse Large B-cell Lymphoma Presenting as Bilateral Renal Masses: Successful Treatment with Dose-adjusted REPOCH (Rituximab, Etoposide, Prednisone, Vincristine, Cycl...
Anahat Kaur, Omar Abughanimeh, Yousaf Zafar, Timothy J. Pluard> ;Cureus. 2019 Jan 2
66 citations
Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles
Robin Imperial, Zaheer Ahmed, Omer M Toor, Cihat Erdogan, Ateeq Khaliq, Paul Case, James Brett Case, Kevin F. Kennedy, Lee S. Cummings, Niklas Melton, Shahzad Raza, Ba...> ;Molecular Cancer. 2018 Dec 21
9 citations
Correction: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma [J Transl Med., 16, (...
Linda M. Liau, Keyoumars Ashkan, David Tran, Jian Campian, John E. Trusheim, Charles S. Cobbs, Jason Heth, Michael Salacz, Sarah A. Taylor, Stacy D. D’Andre, Fabio M. ...> ;Journal of Translational Medicine. 2018 Jun 29
163 citations
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.
Linda M Liau, Keyoumars Ashkan, David D Tran, Jian L Campian, John E Trusheim, Charles S Cobbs, Jason A Heth, Michael Salacz, Sarah Taylor, Stacy D D'Andre, Fabio M Iw...> ;Journal of Translational Medicine. 2018 May 29
83 citations
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Sonia Pernas, Miguel Martin, Peter A. Kaufman, M. Gil-Martin, Patricia Gomez Pardo, Sara López-Tarruella, Luis Manso, Eva Ciruelos, Jose Alejandro Perez-Fidalgo, Crist...> ;The Lancet. Oncology. 2018 Jun 1
41 citations
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Barbara Pistilli, T. Pluard, Ander Urruticoechea, D. Farci, Anthony Kong, Thomas Bachelot, Steve Chan, H. S. Han, Guy Jerusalem, Patrick Urban, Douglas Robinson, S. L....> ;Breast Cancer Research and Treatment. 2018 Apr 1
34 citations
First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
Wolfgang Janni, Emilio Alba, Thomas Bachelot, Sami Diab, Miguel Gil-Gil, Thaddeus Beck, Larisa Ryvo, Rafael López, Michaela Tsai, Francisco J. Esteva, Pilar Zamora Auñ...> ;Breast Cancer Research and Treatment. 2018 Feb 5
57 citations
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Cynthia X. Ma, César Sánchez, Feng Gao, Robert J. Crowder, Michael Naughton, Timothy J. Pluard, Allison N. Creekmore, Zhanfang Guo, Jeremy Hoog, A. Craig Lockhart, Aus...> ;Clinical Cancer Research. 2016 Jun 1
18 citations
Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
Omer M Toor, Zaheer Ahmed, Waled Bahaj, Urooge Boda, Lee S. Cummings, Megan E. McNally, Kevin F. Kennedy, Timothy J. Pluard, Arif Hussain, Janakiraman Subramanian, Ash...> ;Molecular Cancer Therapeutics. 2018 Jan 1
362 citations
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3...
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,...> ;The Lancet. Oncology. 2017 Dec 1
33 citations
Ral signaling pathway in health and cancer.
Adel Rezaei Moghadam, Elham Patrad, Elham Tafsiri, Warner Peng, Benjamin Fangman, Timothy J. Pluard, Anthony Accurso, Michael Salacz, Kushal J. Shah, Brandon Ricke, Da...> ;Cancer Medicine. 2017 Dec 1
134 citations
Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.
Cynthia X. Ma, Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric P. Winer, Michael Naughton, Matthew P. Goetz, Christy A. Russell, Debu ...> ;Clinical Cancer Research. 2017 Oct 1
7 citations
Ezh2, a novel target in detection and therapy of breast cancer.
Sarah Pourakbar, Timothy J. Pluard, Anthony Accurso, Faris Farassati> ;Oncotargets and Therapy. 2017 May 22
Join now to see all

Lectures

The Utility of Hereditary Thrombophilia Testing Among Hospitalized Patients: A Single Center Experience
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Highlights of the 2011 San Antonio Breast Cancer Symposium
Washington University School of Medicine, Saint Louis, Missouri - 2/11/2012

Press Mentions

The Power of Metastatic Breast Cancer Retreats with Lillie Shockney and Janie Metsker: Part 1October 28th, 2022
Saint Luke's Cancer Institute & Patient Discovery Launches Innovative Digital Advocate for Advance Care PlanningJune 10th, 2021
Anova Announces Formation of Scientific Advisory Board to Advance Development of Its Technology Platform Transforming Clinical DevelopmentOctober 7th, 2020
Join now to see all